Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Proof-of-Concept, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 in Major Depressive Disorder

Next Previous
X
Search
Trial Profile

A Proof-of-Concept, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 in Major Depressive Disorder

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Encukalner (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms X-NOVA
  • Sponsors Xenon Pharmaceuticals

    • Most Recent Events

    • 08 Aug 2024 According to a Xenon Pharmaceuticals media release, company anticipates the first of three planned Phase 3 clinical trials is expected to initiate in the second half of 2024
    • 28 May 2024 According to a Xenon Pharmaceuticals media release, data from this study presented at the American Society of Clinical Psychopharmacology (ASCP) 2024 Annual Meeting in Miami, FL.
    • 28 May 2024 Results presented in a Xenon Pharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top